Jacob I. Stuckey
Research Subjects
Jacob I. Stuckey has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Côté
Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts. 1
47 shared publications - Avinash Khanna
Hansoh Bio, LLC, 9900 Medical Center Drive, Suite 200, Rockville, Maryland 20850, United States
47 shared publications - Drew Rasco
The START Center for Cancer Research, San Antonio, Texas
47 shared publications - Elizabeth J. Adams
Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts. 1
47 shared publications - Feng Zhao
Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts. 1
47 shared publications - Jennifer A. Mertz
Constellation Pharmaceuticals, A MorphoSys Company, Boston, Massachusetts. 1
47 shared publications
Latest Publications
- 1 September 2026
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 65 (18) , 2851-2864
Thermodynamic Insights into the WT and Y220C TP53 DBDs Reveal that the Oncogenic Y220C Variant is a Loss-of-Function Mutation for Zn2+-Binding at Physiological Temperature
We present evidence of previously unrecognized allosteric connectivity across the TP53 DNA-binding domain (DBD). Specifically, we have found evidence of an explicit influence on the Zn2+-binding site from the region surrounding the hotspot Y220C mutation. This allosteric connectivity is intertwined with a temperature-dependent destabilization of Zn2+ binding in both the WT and the Y220C DBDs. Our studies indicate that the Y220C mutation exacerbates this temperature-dependent destabilization of Zn2+ binding to result in overall destabilization of the Y220C variant. We provide detailed thermodynamic evidence that Rezatapopt, a small molecule reactivator of the Y220C DBD, engages Y220C through two thermodynamically distinct binding mechanisms and restores WT-level Zn2+-affinity to this oncogenic variant. A series of thermodynamic models describing the WT and Y220C conformational landscapes as well as the Rezatapopt binding mechanisms are proposed.
- 1 September 2026
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 65 (18) , 2851-2864
Thermodynamic Insights into the WT and Y220C TP53 DBDs Reveal that the Oncogenic Y220C Variant is a Loss-of-Function Mutation for Zn2+-Binding at Physiological Temperature
We present evidence of previously unrecognized allosteric connectivity across the TP53 DNA-binding domain (DBD). Specifically, we have found evidence of an explicit influence on the Zn2+-binding site from the region surrounding the hotspot Y220C mutation. This allosteric connectivity is intertwined with a temperature-dependent destabilization of Zn2+ binding in both the WT and the Y220C DBDs. Our studies indicate that the Y220C mutation exacerbates this temperature-dependent destabilization of Zn2+ binding to result in overall destabilization of the Y220C variant. We provide detailed thermodynamic evidence that Rezatapopt, a small molecule reactivator of the Y220C DBD, engages Y220C through two thermodynamically distinct binding mechanisms and restores WT-level Zn2+-affinity to this oncogenic variant. A series of thermodynamic models describing the WT and Y220C conformational landscapes as well as the Rezatapopt binding mechanisms are proposed.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Table with cell line information including source and RRID
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Table with cell line information including source and RRID
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
List of 365 genes (used in main Fig. 7F) that are induced in patient’s whole blood upon treatment with tulmimetostat
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
List of 365 genes (used in main Fig. 7F) that are induced in patient’s whole blood upon treatment with tulmimetostat
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Summary of PK data for EZH2 inhibitors used in KARPAS-422 and HT1376 xeograft mmouse models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Summary of PK data for EZH2 inhibitors used in KARPAS-422 and HT1376 xeograft mmouse models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
List of 365 genes (used in main Fig. 7F) that are induced in patient’s whole blood upon treatment with tulmimetostat
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
List of 365 genes (used in main Fig. 7F) that are induced in patient’s whole blood upon treatment with tulmimetostat
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Tulmimetostat increases PRC2-repressed gene expression in ARID1A mutant bladder cancer cells. (
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Tulmimetostat increases PRC2-repressed gene expression in ARID1A mutant bladder cancer cells. (
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Additional method information to describe technical aspects of the experiments described in this manuscript
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Additional method information to describe technical aspects of the experiments described in this manuscript
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Table with antibody source information including RRID if available
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Table with antibody source information including RRID if available
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Tulmimetostat treatment results in greater PRC2 target gene expression induction in phenotypically sensitive ARID1A LOF cell lines
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Tulmimetostat treatment results in greater PRC2 target gene expression induction in phenotypically sensitive ARID1A LOF cell lines
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Tulmimetostat mediated cancer cell phenotypic responses are increased in ARID1A LOF contexts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Tulmimetostat mediated cancer cell phenotypic responses are increased in ARID1A LOF contexts.